The difficulty in defining the true high-risk smoldering myeloma
Early intervention trials have been initiated for the precursor disease smoldering myeloma (SMM). A recent study showed that genomic complexity varies widely among patients treated for high-risk SMM and is associated with response to triplet therapy, suggesting that established clinical risk scores...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
1 October 2024
|
| In: |
Clinical cancer research
Year: 2024, Volume: 30, Issue: 19, Pages: 4263-4265 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-24-1382 |
| Online Access: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1158/1078-0432.CCR-24-1382 Verlag, lizenzpflichtig, Volltext: https://aacrjournals.org/clincancerres/article-abstract/30/19/4263/748542 
|
| Author Notes: | Niels Weinhold, Leo Rasche |
| Summary: | Early intervention trials have been initiated for the precursor disease smoldering myeloma (SMM). A recent study showed that genomic complexity varies widely among patients treated for high-risk SMM and is associated with response to triplet therapy, suggesting that established clinical risk scores often fail to discriminate between stable and aggressive disease.See related article by Kazandjian et al., p. 4482 |
|---|---|
| Item Description: | Gesehen am 22.04.2025 |
| Physical Description: | Online Resource |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-24-1382 |